Status | Study |
Not yet recruiting |
Study Name: Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Condition: Idiopathic Angioedema Date: 2016-11-15 Interventions: Drug: Omalizumab Omalizumab 30 |
Completed |
Study Name: Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema Condition: ACE-I and ARB-induced Angioedema. Date: 2016-07-05 |
Active, not recruiting |
Study Name: Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Condition: Hereditary Angioedema Date: 2016-04-08 Interventions: Drug: DX-2930 Rollover subject |
Active, not recruiting |
Study Name: Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Condition: Hereditary Angioedema Date: 2015-10-23 Interventions: Drug: DX-2930 - 300mg/2wk 300 |
Completed |
Study Name: Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects Condition: Hereditary Angioedema Date: 2014-03-17 Interventions: Drug: DX-2930 DX-2930 is a rec |
Completed |
Study Name: A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Condition: Hereditary Angioedema Types I and II Date: 2013-07-29 Interventions: Biological: Low-volume C1-esterase inhibitor |
Recruiting |
Study Name: Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema Condition: Acute ACE-induced Angioedema Date: 2013-04-26 Interventions: Drug: Berinert Drug: Clemastin |
Completed |
Study Name: Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks Condition: Hereditary Angioedema Date: 2012-06-29 Interventions: Biological: CINRYZE with rHuPH20 Other Names: C1 esterase inhibitor (hu |
Terminated |
Study Name: Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Condition: ACE Inhibitor-associated Angioedema Date: 2011-12-14 Interventions: Drug: icatibant Subcutaneous a |
Active, not recruiting |
Study Name: A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Condition: Hereditary Angioedema (HAE) Date: 2011-06-28 Interventions: Drug: icatibant Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg |